LSTAHIGH SIGNALMANAGEMENT10-K

LSTA entered into a merger agreement with Kuva Labs Inc. on March 6, 2026, representing a significant corporate transaction coinciding with substantial financial deterioration.

The merger announcement indicates a potential exit strategy for shareholders, which may be driven by the company's declining financial position and cash burn rate. This represents a material change in the investment thesis, as shareholders will likely receive consideration from Kuva rather than continuing to hold LSTA equity, fundamentally altering the risk-return profile of the investment.

Comparing 2026-03-12 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

LSTA's financials show a mixed picture with revenue growing 56.9% to $35.3M and R&D expenses surging 91.1% to $17.7M, while the balance sheet contracted dramatically with stockholders' equity and total assets both declining approximately 50% to $14.9M and $17.7M respectively. Operating losses improved 18.7% and operating cash flow losses decreased to -$15.9M, but the overall picture suggests significant cash burn and balance sheet deterioration that likely necessitated the merger transaction. The company appears to have been burning through its capital base while scaling R&D investments, creating an unsustainable trajectory absent external financing or strategic alternatives.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
+91.1%
$9.3M→$17.7M

R&D investment increased 91.1% — signals commitment to future product development, though near-term margin impact.

Revenue
P&L
+56.9%
$22.5M→$35.3M

Strong top-line growth of 56.9% — accelerating demand or successful expansion into new markets.

Stockholders Equity
Balance Sheet
-49.8%
$29.6M→$14.9M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Assets
Balance Sheet
-49.3%
$35.0M→$17.7M

Total assets contracted 49.3% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-48.8%
$34.6M→$17.7M

Current assets declined 48.8% — monitor working capital adequacy and short-term liquidity.

Current Liabilities
Balance Sheet
-45.3%
$5.6M→$3.1M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-44.7%
$5.7M→$3.1M

Liabilities reduced 44.7% — deleveraging improves balance sheet strength and financial flexibility.

Gross Profit
P&L
-27.7%
$2.4M→$1.7M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Operating Income
P&L
+18.7%
-$22.4M→-$18.2M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Operating Cash Flow
Cash Flow
+17.6%
-$19.4M→-$15.9M

Operating cash flow grew 17.6% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-02-27
ADDED
Our investigational product, certepetide (formerly known as LSTA1 or CEND-1), is designed to activate a novel uptake pathway (the C-end rule active transport mechanism) that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
We, our collaborators and other researchers have amassed and continue to amass significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics.
In addition, certain preclinical data using certepetide in combination with antibody drug conjugates (ADCs) has been generated as part of our research collaboration with Catalent.
These data were presented at a scientific meeting during the fourth quarter of 2025.
To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy, with and without added immunotherapy, for pancreatic cancer.
On March 6, 2026, we entered into an Agreement and Plan of Merger (the Merger Agreement ) with Kuva Labs Inc., a Delaware corporation ( Kuva ), and Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Kuva ( Purchaser ).
New York City Time on the seventh (7th) anniversary of the Closing Date (as 5 defined in the Merger Agreement), and (b) termination of the CVR Agreement (the Milestone ), in accordance with the terms and subject to the conditions of a contingent value rights agreement (the CVR Agreement ) to be entered into with a rights agent selected by Kuva and reasonably acceptable to us (the Closing Amount plus one CVR, collectively, the Offer Price ).
If certain conditions are satisfied and the Offer is consummated, Kuva would acquire any remaining Common Shares for the Offer Price by a merger of Purchaser with and into us (the Merger ).
The obligation of Purchaser to consummate the Offer is also subject to other customary conditions.
Consummation of the Offer is not subject to a financing condition.
REMOVED
Our investigational product, certepetide (formerly known as LSTA1 or CEND-1), is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
We and our collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics.
To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer.
We are exploring certepetide as a means to enable a variety of treatment modalities to treat a range of solid tumors more effectively.
Additionally, the Company is currently exploring applications of certepetide in melanoma (skin cancer) in collaboration with Valo Therapeutics of Finland as well as in endometriosis (a non-cancer disease that behaves much like a solid tumor) in collaboration with the University of Cincinnati (USA).
Development Programs Targeted Solid Tumor Penetration via CendR Active Transport Many solid tumor cancers, including, for example, pancreatic ductal adenocarcinoma ( PDAC ) and cholangiocarcinoma, are surrounded by dense fibrotic tissue, known as the tumor stroma.
This stroma often limits the efficacy of current chemotherapies in the treatment of these cancers by impeding the penetration of anti-cancer therapies into the tumor.
To address the tumor stroma s role as a key impediment to effective treatment, our approach is to activate the C-end rule ( CendR ), or CendR active transport mechanism, a naturally occurring transport system.
For example, preliminary results of the combination of certepetide with immunotherapy and chemotherapy are promising.
Lisata, its collaborators, and research groups around the world have published more than 370 scientific papers related to the benefits of internalizing RGD peptides and the CendR pathway.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →